Therefore, because of the effects of hyper-angiogenesis on the immune makeup of the TME, especially in promoting pro-tumour immune populations, anti-angiogenic agents can be beneficial and supplement the anti-tumour effects of anti-PD-1/PD-L1 blockade. Here, PDCD1 is linked to neoplasm.